AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8121974 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 80
Study 2678686 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha interferons
Number of subjects: 5000
Study 334209 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (7.5 mg and 15 mg)
Number of subjects: 70
Study 334209 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyzine (75 mg and 150 mg)
Number of subjects: 70
Study 30484730 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention (delivered via Skype or face-to-face sessions)
Number of subjects: 113
Study 30484730 — intervention group
Group type: COMPARATOR
Intervention: Control/care-as-usual group
Number of subjects: 113
Study 30484730 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 113
Study 28150186 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin
Number of subjects: 1161
Study 25383558 — intervention group
Group type: EXPERIMENTAL
Intervention: Multitarget therapy (tacrolimus 4 mg/d and mycophenolate mofetil 1.0 g/d)
Number of subjects: 362
Study 25383558 — intervention group
Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (0.75 g/m2 every 4 weeks for 6 months)
Number of subjects: 362
Study 23816018 — intervention group
Group type: EXPERIMENTAL
Intervention: cTnT (fourth-generation Roche assay)
Number of subjects: 1247
Study 23816018 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT
Number of subjects: 1247
Study 23816018 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cTnT with copeptin
Number of subjects: 1247
Study 23816018 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hs-cTnT with copeptin
Number of subjects: 1247
Study 23816018 — intervention group
Group type: EXPERIMENTAL
Intervention: cTnT
Number of subjects: 1247
Study 23816018 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of cTnT and copeptin
Number of subjects: 1247
Study 23816018 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of hs-cTnT and copeptin
Number of subjects: 1247
Study 21681372 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (NP chemotherapy followed by vaccination with CEA (605-613) peptide-pulsed autologous dendritic cells and CIK cells, repeated at 30-day intervals for 4 cycles)
Number of subjects: 28
Study 21681372 — intervention group
Group type: COMPARATOR
Intervention: Conventional NP chemotherapy
Number of subjects: 28
Study 19788736 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyostypt
Number of subjects: 28
Study 19788736 — intervention group
Group type: COMPARATOR
Intervention: Surgicel
Number of subjects: 28
Study 17276750 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.25 mg/kg
Number of subjects: 66
Study 17276750 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.5 mg/kg
Number of subjects: 66
Study 17276750 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.125 mg/kg
Number of subjects: 66
Study 17276750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 15352149 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting risperidone (25, 50, or 75 mg every 2 weeks for up to 50 weeks)
Number of subjects: 57
Study 15352149 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting risperidone
Number of subjects: 57
Study 11359333 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperitoneal approach
Number of subjects: 20
Study 11359333 — intervention group
Group type: COMPARATOR
Intervention: Extraperitoneal approach
Number of subjects: 20
Study 9681160 — intervention group
Group type: EXPERIMENTAL
Intervention: Y-connector technique (IY)
Number of subjects: 60
Study 9681160 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique (CY)
Number of subjects: 60
Study 9681160 — intervention group
Group type: COMPARATOR
Intervention: Standard spikes (IS)
Number of subjects: 60
Study 9681160 — intervention group
Group type: COMPARATOR
Intervention: Standard spikes (CS)
Number of subjects: 60
Study 8043247 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% lidocaine injection
Number of subjects: 58
Study 8043247 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 58
Study 2968761 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin (pernasally in conventional doses)
Number of subjects: 107
Study 2968761 — intervention group
Group type: EXPERIMENTAL
Intervention: Decapeptyl (intramuscularly in 5-week intervals)
Number of subjects: 107
Study 2968761 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LHRH analogues (Buserelin and Decapeptyl)
Number of subjects: 107
Study 2968761 — intervention group
Group type: EXPERIMENTAL
Intervention: PAP and PSA tumor markers
Number of subjects: 107
Study 31735531 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric resistance exercise
Number of subjects: 21
Study 31735531 — intervention group
Group type: COMPARATOR
Intervention: Dynamic resistance exercise
Number of subjects: 21
Study 30839075 — intervention group
Group type: EXPERIMENTAL
Intervention: CGAE supplementation at 1,000 mg/kg
Number of subjects: 400
Study 30839075 — intervention group
Group type: COMPARATOR
Intervention: HT group
Number of subjects: 400
Study 28388458 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear subtypes linked to performance situations
Number of subjects: 131
Study 28388458 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear subtypes linked to observation situations
Number of subjects: 131
Study 28388458 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear subtypes linked to interaction situations
Number of subjects: 131
Study 28388458 — intervention group
Group type: EXPERIMENTAL
Intervention: Avoidance responses
Number of subjects: 131
Study 28388458 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall findings
Number of subjects: 131
Study 28388458 — intervention group
Group type: EXPERIMENTAL
Intervention: Distinct contributions of fear and avoidance
Number of subjects: 131
Study 25701812 — intervention group
Group type: EXPERIMENTAL
Intervention: PM mass (<2.5μm) and particle number concentrations (PNCs) in six size fractions during two forty-eight hour sampling periods
Number of subjects: 96
Study 25701812 — intervention group
Group type: EXPERIMENTAL
Intervention: Household income
Number of subjects: 96
Study 25701812 — intervention group
Group type: EXPERIMENTAL
Intervention: Time of day
Number of subjects: 96
Study 25701812 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltration efficiency
Number of subjects: 96
Study 23228270 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical preparation size 35.06 to 40.04
Number of subjects: 155
Study 23228270 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical preparation taper from 40.04 to 40.06 in group B
Number of subjects: 155
Study 23228270 — intervention group
Group type: EXPERIMENTAL
Intervention: Apical preparation sizes greater than 40.06
Number of subjects: 155
Study 23228270 — intervention group
Group type: COMPARATOR
Intervention: Positive control: maximum volume of 5.25% NaOCl from an open glass vial
Number of subjects: 155
Study 23228270 — intervention group
Group type: COMPARATOR
Intervention: Negative control: preparation size of 25.04
Number of subjects: 155
Study 21570027 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrophilic-coated catheter (SpeediCath)
Number of subjects: 224
Study 21570027 — intervention group
Group type: COMPARATOR
Intervention: Uncoated catheter (Conveen)
Number of subjects: 224
Study 19591898 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS)
Number of subjects: 21
Study 19591898 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalamotomy (TH)
Number of subjects: 21
Study 19591898 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 21
Study 16808770 — intervention group
Group type: EXPERIMENTAL
Intervention: Full disclosure of medical errors
Number of subjects: 407
Study 16808770 — intervention group
Group type: COMPARATOR
Intervention: Nondisclosure of medical errors
Number of subjects: 407
Study 16808770 — intervention group
Group type: COMPARATOR
Intervention: Missed allergy error condition (Nondisclosure)
Number of subjects: 407
Study 16808770 — intervention group
Group type: COMPARATOR
Intervention: Monitoring error condition (Nondisclosure)
Number of subjects: 407
Study 16808770 — intervention group
Group type: COMPARATOR
Intervention: Positive physician-patient relationship
Number of subjects: 407
Study 16808770 — intervention group
Group type: COMPARATOR
Intervention: Waiving costs associated with the error
Number of subjects: 407
Study 14698362 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 1 microg.mL(‐1) at rate of 0.2 mL.kg ‐1.h ‐1 preceded by a bolus of 2 microg.kg ‐1 (CLON group)
Number of subjects: 40
Study 14698362 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 1 microg.mL ‐1 and ropivacaine 0.1% at rate of 0.2 mL.kg ‐1.h ‐1 (CLON+ROPIV group)
Number of subjects: 40
Study 14698362 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (both groups)
Number of subjects: 40
Study 14698362 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 10652960 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone plus 15 mg of menatetrenone, three times per day (Group 2)
Number of subjects: 20
Study 10652960 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone alone (Group 1)
Number of subjects: 20
Study 9315428 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 9014
Study 9315428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9014
Study 8364946 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb 761) 320 mg
Number of subjects: 18
Study 8364946 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb 761) 600 mg
Number of subjects: 18
Study 8364946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2439787 — intervention group
Group type: EXPERIMENTAL
Intervention: bisoprolol (10 mg)
Number of subjects: 19
Study 2439787 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol (100 mg)
Number of subjects: 19
Study 29484546 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-TGF (sodium fluoride NaF associated with tara gum, 1100 mg/L)
Number of subjects: 18
Study 29484546 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-TGF (50% NaF associated with tara gum + 50% free NaF, 1100 mg/L)
Number of subjects: 18
Study 29484546 — intervention group
Group type: EXPERIMENTAL
Intervention: PC (free NaF, 1100 mg/L)
Number of subjects: 18
Study 29484546 — intervention group
Group type: EXPERIMENTAL
Intervention: TG (with tara gum and without F)
Number of subjects: 18
Study 29484546 — intervention group
Group type: COMPARATOR
Intervention: Placebo (without F or tara gum)
Number of subjects: 18
Study 27596550 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg per day
Number of subjects: 56
Study 27596550 — intervention group
Group type: COMPARATOR
Intervention: Voglibose 0.2 mg for 3 times per day
Number of subjects: 56
Study 24316704 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 24
Study 24316704 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% prilocaine with 1:1.850,000 felypressin
Number of subjects: 24
Study 24316704 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anesthetic procedures)
Number of subjects: 24
Study 24316704 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 24
Study 22683041 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 2331
Study 22683041 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak oxygen consumption (Vo(2))
Number of subjects: 2331
Study 22683041 — intervention group
Group type: EXPERIMENTAL
Intervention: E/A ratio and peak Vo(2)
Number of subjects: 2331
Study 22683041 — intervention group
Group type: EXPERIMENTAL
Intervention: E/E' ratio
Number of subjects: 2331
Study 22683041 — intervention group
Group type: EXPERIMENTAL
Intervention: E/A ratio
Number of subjects: 2331
Study 22683041 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic variables
Number of subjects: 2331
Study 20188357 — intervention group
Group type: EXPERIMENTAL
Intervention: Single cell extraction from karyotypically defined cell lines
Number of subjects: 78
Study 18216600 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF
Number of subjects: 166
Study 18216600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 16424844 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA+GA, poor ventricular function (Group TEA+GA plus PV)
Number of subjects: 80
Study 16424844 — intervention group
Group type: EXPERIMENTAL
Intervention: TEA+GA, good ventricular function (Group TEA+GA plus GV)
Number of subjects: 80
Study 16424844 — intervention group
Group type: COMPARATOR
Intervention: GA, poor ventricular function (Group GA plus PV)
Number of subjects: 80
Study 16424844 — intervention group
Group type: COMPARATOR
Intervention: GA, good ventricular function (Group GA plus GV)
Number of subjects: 80
Study 12859464 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (50 microg single dose)
Number of subjects: 24
Study 12859464 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl (50 microg single dose)
Number of subjects: 24
Study 10368939 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task condition (lexical decision with auditory probe)
Number of subjects: 2
Study 10368939 — intervention group
Group type: COMPARATOR
Intervention: Control condition (lexical decision alone)
Number of subjects: 2
Study 10368939 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task condition (tone detection with auditory probe)
Number of subjects: 2
Study 10368939 — intervention group
Group type: COMPARATOR
Intervention: Tones in isolation
Number of subjects: 2
Study 10368939 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing SOA (stimulus onset asynchronies)
Number of subjects: 2
Study 10368939 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task condition
Number of subjects: 2
Study 8571910 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg Fe/kg of AMI 227
Number of subjects: 16
Study 8571910 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1 mg Fe/kg of AMI 227
Number of subjects: 16
Study 8571910 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.7 mg Fe/kg of AMI 227
Number of subjects: 16
Study 8571910 — intervention group
Group type: COMPARATOR
Intervention: Control (unenhanced images)
Number of subjects: 16
Study 1900009 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rt-PA)
Number of subjects: 312
Study 6207964 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin
Number of subjects: 0
Study 6207964 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin
Number of subjects: 0
Study 6207964 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and Bleomycin (synergistic effect)
Number of subjects: 0
Study 30531232 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-week stabilization exercise therapy program, 60 mins/week
Number of subjects: 57
Study 28552588 — intervention group
Group type: EXPERIMENTAL
Intervention: 4400 IU/d vitamin D3 supplementation
Number of subjects: 51
Study 28552588 — intervention group
Group type: COMPARATOR
Intervention: 400 IU/d vitamin D3 supplementation
Number of subjects: 51
Study 27400423 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tPCS (10 min)
Number of subjects: 40
Study 27400423 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tPCS (20 min)
Number of subjects: 40
Study 27400423 — intervention group
Group type: COMPARATOR
Intervention: Sham tPCS
Number of subjects: 40
Study 25240992 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural formulation containing tea catechins
Number of subjects: 60
Study 25240992 — intervention group
Group type: COMPARATOR
Intervention: Placebo (xylitol-containing)
Number of subjects: 60
Study 25240992 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (catechin and placebo)
Number of subjects: 60
Study 22218626 — intervention group
Group type: EXPERIMENTAL
Intervention: CRC screening intervention
Number of subjects: 1685
Study 20031222 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication group
Number of subjects: 1636
Study 20031222 — intervention group
Group type: COMPARATOR
Intervention: Observation group
Number of subjects: 1636
Study 17922560 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT (tegafur-uracil) plus leucovorin given as two daily doses (bid)
Number of subjects: 21
Study 17922560 — intervention group
Group type: COMPARATOR
Intervention: UFT (tegafur-uracil) plus leucovorin given as three daily doses (tid)
Number of subjects: 21
Study 16195572 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviourally specified 'plain English' guidelines
Number of subjects: 84
Study 16195572 — intervention group
Group type: COMPARATOR
Intervention: Original text of the NICE public guidelines
Number of subjects: 84
Study 12734607 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine 16 mg once-a-day
Number of subjects: 42
Study 12734607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 10338458 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose transdermal nitroglycerin (NTG) 50 to 100 mg daily for 12 hours
Number of subjects: 29
Study 10338458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 7723644 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice-packet vest (V)
Number of subjects: 6
Study 7723644 — intervention group
Group type: EXPERIMENTAL
Intervention: Refrigerated headpiece (H)
Number of subjects: 6
Study 7723644 — intervention group
Group type: COMPARATOR
Intervention: No cooling (C)
Number of subjects: 6
Study 2045181 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet (200 meq sodium per day)
Number of subjects: 17
Study 2045181 — intervention group
Group type: COMPARATOR
Intervention: Low sodium diet (10 meq sodium per day)
Number of subjects: 17
Study 6994786 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (3 mg daily)
Number of subjects: 16
Study 6994786 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanethidine (20 mg daily)
Number of subjects: 16
Study 31126603 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printed ultrasound-compatible vascular models (3DPVAM)
Number of subjects: 49
Study 31126603 — intervention group
Group type: COMPARATOR
Intervention: Commercial model (CM)
Number of subjects: 49
Study 28816589 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher acculturation
Number of subjects: 282
Study 28816589 — intervention group
Group type: EXPERIMENTAL
Intervention: Acculturation score increase
Number of subjects: 282
Study 25739586 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart (Asp)
Number of subjects: 12
Study 25739586 — intervention group
Group type: COMPARATOR
Intervention: Insulin glulisine (Glu)
Number of subjects: 12
Study 23932834 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy with lavender essential oil
Number of subjects: 48
Study 23932834 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (10-15 mg/kg/dose, PO) every 6h as necessary
Number of subjects: 48
Study 21270331 — intervention group
Group type: EXPERIMENTAL
Intervention: Food deficit
Number of subjects: 12
Study 21270331 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise deficit
Number of subjects: 12
Study 21270331 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study 19560316 — intervention group
Group type: EXPERIMENTAL
Intervention: JTech PowerTrack II hand-held dynamometer
Number of subjects: 38
Study 19560316 — intervention group
Group type: COMPARATOR
Intervention: LIDO WorkSET stationary dynamometer
Number of subjects: 38
Study 16457935 — intervention group
Group type: EXPERIMENTAL
Intervention: CPREzy feedback device
Number of subjects: 224
Study 16457935 — intervention group
Group type: COMPARATOR
Intervention: Control group (no feedback device)
Number of subjects: 224
Study 15271272 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in breast cancer prevention clinical trial
Number of subjects: 180
Study 15271272 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in coronary heart disease prevention clinical trial
Number of subjects: 180
Study 15271272 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians' recommendations for participation
Number of subjects: 180
Study 15271272 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived risk of disease
Number of subjects: 180
Study 15271272 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk information received from doctors
Number of subjects: 180
Study 15271272 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of clinical trials
Number of subjects: 180
Study 12616844 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9706526 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine + prilocaine (active group)
Number of subjects: 119
Study 9706526 — intervention group
Group type: COMPARATOR
Intervention: Aqueous extract of Triticum vulgaris (placebo group)
Number of subjects: 119
Study 9706526 — intervention group
Group type: COMPARATOR
Intervention: No anesthetic (control group)
Number of subjects: 119
Study 8520640 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.2 MJ diet daily with exercise
Number of subjects: 98
Study 8520640 — intervention group
Group type: COMPARATOR
Intervention: 4.2 MJ diet daily without exercise
Number of subjects: 98
Study 2146047 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol 600 mg daily for 6 months
Number of subjects: 30
Study 2146047 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin 3.6 mg monthly depot injections for 6 months
Number of subjects: 30
Study 386157 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone and cyclophosphamide pretreatment (5 g each)
Number of subjects: 34
Study 386157 — intervention group
Group type: COMPARATOR
Intervention: Control (no pretreatment)
Number of subjects: 34
Study 386157 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone and cyclophosphamide pretreatment
Number of subjects: 34
Study 31994303 — intervention group
Group type: EXPERIMENTAL
Intervention: 270 mg ferrous sulphate twice a day (total elemental iron dose: 160 mg/day)
Number of subjects: 0
Study 31994303 — intervention group
Group type: EXPERIMENTAL
Intervention: 270 mg ferrous sulphate once a day (total elemental iron dose: 80 mg/day)
Number of subjects: 0